Key result
Sacubitril/valsartan and empagliflozin linked to increased LVEF, LVEDD, and LVEDV in chronic HF.
Why the study?
Does the combination of sacubitril/valsartan and empagliflozin improve intracardiac hemodynamics and NT-proBNP in patients with chronic heart failure?
Observational
Does the combination of sacubitril/valsartan and empagliflozin improve intracardiac hemodynamics and NT-proBNP in patients with chronic heart failure?
The use of sacubitril/valsartan and empagliflozin is associated with significant changes in left ventricular dimensions and ejection fraction in patients with chronic heart failure.
Answers are grounded in this paper and cite their sources.
May warrant consideration of combined sacubitril/valsartan and empagliflozin in chronic HF; leaves open confirmation in randomized outcome trials.
This article presents a comparative study of the effects of various standard treatment regimens on intracardiac hemodynamics and N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure, who were divided into three groups for observation. A highly significant increase in the left ventricular end-diastolic dimension, diastolic volume, and ejection fraction was detected in the third group of patients. This confirms the high cardioprotective effect of sacubitril/valsartan and empagliflozin.
No takes yet. Share an insight, caveat, or question.
Hikmatov et al. (2026) conducted an observational in chronic heart failure. empagliflozin and sacubitril/valsartan vs. standard treatment regimens was evaluated on intracardiac hemodynamics and N-terminal pro-B-type natriuretic peptide. Sacubitril/valsartan and empagliflozin demonstrated a highly significant increase in left ventricular end-diastolic dimension, diastolic volume, and ejection fraction in chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: